Complete financial analysis of Charles River Laboratories International, Inc. (CRL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Charles River Laboratories International, Inc., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- Fox Marble Holdings PLC (FOX.L) Income Statement Analysis – Financial Results
- Procorp, S.A.B. de C.V. (PROCORPB.MX) Income Statement Analysis – Financial Results
- EQ Energy Drink, Inc. (EQLB) Income Statement Analysis – Financial Results
- Inner Mongolia Furui Medical Science Co., Ltd. (300049.SZ) Income Statement Analysis – Financial Results
- Goliath Resources Limited (GOT.V) Income Statement Analysis – Financial Results
Charles River Laboratories International, Inc. (CRL)
About Charles River Laboratories International, Inc.
Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company also provides contract vivarium operation services to biopharmaceutical clients. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.13B | 3.98B | 3.54B | 2.92B | 2.62B | 2.27B | 1.86B | 1.68B | 1.36B | 1.30B | 1.17B | 1.13B | 1.14B | 1.13B | 1.20B | 1.34B | 1.23B | 1.06B | 1.12B | 766.92M | 613.72M | 554.63M | 465.63M | 306.59M | 219.28M | 193.30M |
| Cost of Revenue | 2.63B | 2.51B | 2.21B | 1.85B | 1.66B | 1.43B | 1.16B | 1.03B | 832.21M | 825.00M | 770.63M | 737.45M | 740.41M | 748.66M | 773.18M | 832.78M | 752.44M | 651.78M | 693.49M | 468.35M | 380.06M | 345.65M | 298.38M | 171.45M | 120.91M | 122.55M |
| Gross Profit | 1.50B | 1.46B | 1.33B | 1.07B | 958.31M | 840.07M | 702.31M | 646.67M | 531.09M | 472.66M | 394.90M | 392.08M | 402.24M | 384.76M | 429.37M | 510.71M | 478.19M | 406.61M | 428.74M | 298.57M | 233.67M | 208.98M | 167.25M | 135.14M | 98.37M | 70.75M |
| Gross Profit Ratio | 36.39% | 36.79% | 37.70% | 36.72% | 36.56% | 37.07% | 37.81% | 38.46% | 38.96% | 36.42% | 33.88% | 34.71% | 35.20% | 33.95% | 35.70% | 38.01% | 38.86% | 38.42% | 38.20% | 38.93% | 38.07% | 37.68% | 35.92% | 44.08% | 44.86% | 36.60% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 747.86M | 665.10M | 619.92M | 528.94M | 517.62M | 443.85M | 373.45M | 367.55M | 300.41M | 269.03M | 225.70M | 208.25M | 206.14M | 262.49M | 234.00M | 230.16M | 217.49M | 180.80M | 189.54M | 121.45M | 90.24M | 83.30M | 68.32M | 51.20M | 39.77M | 34.14M |
| Other Expenses | 0.00 | 146.58M | 124.86M | 111.88M | 89.54M | 13.26M | 38.54M | 11.90M | 3.01M | 10.72M | 7.17M | -3.27M | 21.80M | 24.41M | 28.45M | 30.31M | 33.51M | 37.64M | 58.17M | 16.80M | 4.88M | 3.41M | 8.65M | 18.87M | 15.64M | 1.29M |
| Operating Expenses | 885.30M | 811.68M | 744.78M | 640.81M | 607.16M | 508.68M | 414.82M | 409.25M | 324.64M | 294.99M | 243.50M | 226.32M | 227.94M | 286.89M | 262.44M | 260.47M | 251.00M | 218.43M | 247.72M | 138.24M | 95.11M | 86.72M | 76.97M | 70.07M | 55.41M | 35.43M |
| Cost & Expenses | 3.51B | 3.33B | 2.95B | 2.49B | 2.27B | 1.93B | 1.57B | 1.44B | 1.16B | 1.12B | 1.01B | 963.77M | 968.34M | 1.04B | 1.04B | 1.09B | 1.00B | 870.21M | 941.21M | 606.59M | 475.17M | 432.36M | 375.35M | 241.52M | 176.31M | 157.98M |
| Interest Income | 5.20M | 780.00K | 652.00K | 834.00K | 1.52M | 812.00K | 690.00K | 1.31M | 1.04M | 1.15M | 730.00K | 589.00K | 1.35M | 1.19M | 1.78M | 8.69M | 9.68M | 6.84M | 3.93M | 3.29M | 0.00 | 2.12M | 1.49M | 0.00 | 0.00 | 0.00 |
| Interest Expense | 136.71M | 59.29M | 73.91M | 86.43M | 60.88M | 63.77M | 29.78M | 27.71M | 15.07M | 11.95M | 20.97M | 33.34M | 41.23M | 34.09M | 21.68M | 14.01M | 14.83M | 193.24M | 22.62M | 8.65M | 6.56M | 27.34M | 27.28M | 67.35M | 8.28M | 0.00 |
| Depreciation & Amortization | 314.12M | 303.87M | 265.54M | 234.92M | 198.10M | 161.78M | 131.16M | 126.66M | 24.23M | 25.96M | 17.81M | 18.07M | 21.80M | 24.41M | 28.45M | 30.31M | 88.92M | 85.13M | 104.64M | 48.18M | 31.12M | 25.73M | 28.58M | 18.87M | 15.64M | 10.90M |
| EBITDA | 1.03B | 1.04B | 854.29M | 759.15M | 581.73M | 507.23M | 457.89M | 377.29M | 305.38M | 285.99M | 255.54M | 244.36M | 260.48M | -205.15M | 263.20M | -355.82M | 321.81M | 273.30M | 274.81M | 210.64M | 138.55M | 147.99M | 90.28M | 83.93M | 58.61M | 46.22M |
| EBITDA Ratio | 24.99% | 24.80% | 23.17% | 26.28% | 21.48% | 18.11% | 19.82% | 17.39% | 16.92% | 15.69% | 14.52% | 16.28% | 17.16% | 10.79% | 16.07% | 73.43% | 25.80% | 25.73% | 25.47% | 27.09% | 27.52% | 26.46% | 25.42% | 27.02% | 25.82% | 23.94% |
| Operating Income | 617.26M | 650.98M | 589.86M | 432.73M | 351.15M | 331.38M | 287.50M | 237.42M | 206.45M | 177.67M | 151.40M | 165.77M | 174.31M | -298.51M | 166.93M | -449.76M | 227.19M | 188.17M | 181.02M | 160.32M | 138.55M | 122.27M | 90.28M | 65.06M | 42.96M | 35.33M |
| Operating Income Ratio | 14.95% | 16.37% | 16.66% | 14.80% | 13.40% | 14.62% | 15.48% | 14.12% | 15.14% | 13.69% | 12.99% | 14.68% | 15.25% | -26.34% | 13.88% | -33.48% | 18.46% | 17.78% | 16.13% | 20.90% | 22.58% | 22.04% | 19.39% | 21.22% | 19.59% | 18.27% |
| Total Other Income/Expenses | -35.98M | -27.99M | -109.15M | 14.39M | -47.07M | -49.70M | 8.67M | -14.50M | -11.02M | -75.00K | -13.07M | -36.02M | -41.64M | -35.57M | -17.82M | -10.14M | -9.77M | -11.61M | -17.13M | -9.86M | -5.92M | -37.75M | -27.78M | -39.35M | -10.28M | 507.00K |
| Income Before Tax | 581.28M | 622.99M | 480.71M | 447.11M | 304.08M | 281.68M | 296.96M | 222.92M | 195.43M | 177.60M | 138.33M | 129.75M | 132.66M | -334.08M | 149.11M | -461.01M | 217.42M | 176.56M | 160.41M | 152.53M | 132.63M | 114.40M | 69.48M | 25.71M | 32.69M | 35.83M |
| Income Before Tax Ratio | 14.08% | 15.67% | 13.58% | 15.29% | 11.60% | 12.43% | 15.99% | 13.26% | 14.33% | 13.69% | 11.87% | 11.49% | 11.61% | -29.48% | 12.40% | -34.31% | 17.67% | 16.68% | 14.29% | 19.89% | 21.61% | 20.63% | 14.92% | 8.39% | 14.91% | 18.54% |
| Income Tax Expense | 100.91M | 130.38M | 81.87M | 81.81M | 50.02M | 54.46M | 171.37M | 66.84M | 43.39M | 47.67M | 32.91M | 27.63M | 17.14M | 23.00K | 39.73M | 61.94M | 59.40M | 49.74M | 16.58M | 61.16M | 51.06M | 43.57M | 27.10M | 7.84M | 15.56M | 14.12M |
| Net Income | 474.62M | 486.23M | 390.98M | 364.30M | 252.02M | 226.37M | 123.36M | 154.77M | 149.31M | 126.70M | 102.83M | 97.30M | 109.57M | -336.67M | 114.44M | -521.84M | 154.41M | -55.78M | 142.00M | 89.79M | 80.15M | 50.13M | 35.41M | -11.22M | 17.12M | 23.38M |
| Net Income Ratio | 11.49% | 12.23% | 11.04% | 12.46% | 9.61% | 9.99% | 6.64% | 9.20% | 10.95% | 9.76% | 8.82% | 8.61% | 9.59% | -29.70% | 9.52% | -38.84% | 12.55% | -5.27% | 12.65% | 11.71% | 13.06% | 9.04% | 7.60% | -3.66% | 7.81% | 12.09% |
| EPS | 9.27 | 9.57 | 7.77 | 7.35 | 5.17 | 4.72 | 2.60 | 3.29 | 3.21 | 2.72 | 2.15 | 2.03 | 2.16 | -5.38 | 1.75 | -7.76 | 2.31 | -0.81 | 2.04 | 1.81 | 1.76 | 1.12 | 0.86 | -0.40 | 0.86 | 2.27 |
| EPS Diluted | 9.22 | 9.48 | 7.60 | 7.20 | 5.07 | 4.62 | 2.54 | 3.23 | 3.13 | 2.66 | 2.12 | 2.01 | 2.14 | -5.38 | 1.74 | -7.76 | 2.25 | -0.80 | 1.96 | 1.67 | 1.64 | 1.06 | 0.80 | -0.35 | 0.86 | 2.27 |
| Weighted Avg Shares Out | 51.23M | 50.81M | 50.29M | 49.55M | 48.73M | 47.95M | 47.48M | 47.01M | 46.50M | 46.63M | 47.74M | 47.91M | 50.82M | 62.56M | 65.37M | 67.27M | 66.96M | 68.87M | 69.61M | 49.60M | 45.54M | 44.76M | 41.17M | 28.06M | 19.82M | 10.29M |
| Weighted Avg Shares Out (Dil) | 51.45M | 51.30M | 51.43M | 50.61M | 49.69M | 49.02M | 48.56M | 47.96M | 47.63M | 47.56M | 48.49M | 48.41M | 51.32M | 62.56M | 65.64M | 67.27M | 68.74M | 69.73M | 72.45M | 56.05M | 48.87M | 47.29M | 44.26M | 32.07M | 19.82M | 10.29M |
Charles River Laboratories, in Collaboration With MatTek Corporation, Awarded Grant from the Foundation for Chemistry Research and Initiatives to Advance Research Alternatives
CRL INVESTIGATION ALERT: Johnson Fistel LLP Investigates Charles River Laboratories' Directors and Officers for Breach of Fiduciary Duties
Charles River Laboratories Expands Access to CRADL® Contract Vivarium Space in Somerville
Charles River Laboratories Announces Development of Nonclinical Virtual Control Groups with Sanofi to Reduce the Use of Animals in Research
Charles River Laboratories to Present at William Blair and Jefferies Conferences
Charles River (CRL) Launches Viral Vector Tech Transfer Program
Charles River Laboratories: Fair Valuation Against Fundamentals
Reasons to Hold Charles River (CRL) in Your Portfolio Now
Charles River Launches Viral Vector Tech Transfer Program to Safeguard Gene Therapy Development
Titian Receives Multi-Year Commitment from Charles River for Mosaic Sample Management Software
Source: https://incomestatements.info
Category: Stock Reports